{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:19:40Z","timestamp":1791343180043,"version":"4.3.1"},"reference-count":31,"publisher":"Massachusetts Medical Society","issue":"8","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["208970\/Z\/17\/Z"],"award-info":[{"award-number":["208970\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Karuna Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2021,2,25]]},"DOI":"10.1056\/nejmoa2017015","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T17:02:22Z","timestamp":1614186142000},"page":"717-726","source":"Crossref","is-referenced-by-count":332,"title":["Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia"],"prefix":"10.1056","volume":"384","author":[{"given":"Stephen K.","family":"Brannan","sequence":"first","affiliation":[{"name":"From Karuna Therapeutics, Boston (S.K.B., S.S., A.C.M., S.M.P.); Columbia University Vagelos College of Physicians and Surgeons, New York (J.A.L.); and Indiana University School of Medicine, Indianapolis (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Sawchak","sequence":"additional","affiliation":[{"name":"From Karuna Therapeutics, Boston (S.K.B., S.S., A.C.M., S.M.P.); Columbia University Vagelos College of Physicians and Surgeons, New York (J.A.L.); and Indiana University School of Medicine, Indianapolis (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Miller","sequence":"additional","affiliation":[{"name":"From Karuna Therapeutics, Boston (S.K.B., S.S., A.C.M., S.M.P.); Columbia University Vagelos College of Physicians and Surgeons, New York (J.A.L.); and Indiana University School of Medicine, Indianapolis (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Lieberman","sequence":"additional","affiliation":[{"name":"From Karuna Therapeutics, Boston (S.K.B., S.S., A.C.M., S.M.P.); Columbia University Vagelos College of Physicians and Surgeons, New York (J.A.L.); and Indiana University School of Medicine, Indianapolis (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Paul","sequence":"additional","affiliation":[{"name":"From Karuna Therapeutics, Boston (S.K.B., S.S., A.C.M., S.M.P.); Columbia University Vagelos College of Physicians and Surgeons, New York (J.A.L.); and Indiana University School of Medicine, Indianapolis (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Breier","sequence":"additional","affiliation":[{"name":"From Karuna Therapeutics, Boston (S.K.B., S.S., A.C.M., S.M.P.); Columbia University Vagelos College of Physicians and Surgeons, New York (J.A.L.); and Indiana University School of Medicine, Indianapolis (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","volume":"394","author":"Huhn M","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019;394:939-951.31303314","journal-title":"Lancet"},{"key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht S","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-962.23810019","journal-title":"Lancet"},{"key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia.","volume":"50","author":"Conley RR","year":"2001","unstructured":"Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001;50:898-911.11743944","journal-title":"Biol Psychiatry"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia.","volume":"381","author":"Marder SR","year":"2019","unstructured":"Marder SR, Cannon TD. Schizophrenia. N Engl J Med 2019;381:1753-1761.31665579","journal-title":"N Engl J Med"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra1801490","article-title":"Psychotic disorders.","volume":"379","author":"Lieberman JA","year":"2018","unstructured":"Lieberman JA, First MB. Psychotic disorders. N Engl J Med 2018;379:270-280.30021088","journal-title":"N Engl J Med"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0893-133X(88)90012-7","article-title":"The current status of the dopamine hypothesis of schizophrenia.","volume":"1","author":"Carlsson A","year":"1988","unstructured":"Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-186.3075131","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.mp.4001924","article-title":"Towards a muscarinic hypothesis of schizophrenia.","volume":"12","author":"Raedler TJ","year":"2007","unstructured":"Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007;12:232-246.17146471","journal-title":"Mol Psychiatry"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/npp.2015.189","article-title":"Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model.","volume":"41","author":"Ghoshal A","year":"2016","unstructured":"Ghoshal A, Rook JM, Dickerson JW, et al. Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model. Neuropsychopharmacology 2016;41:598-610.26108886","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.160.1.118","article-title":"In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia.","volume":"160","author":"Raedler TJ","year":"2003","unstructured":"Raedler TJ, Knable MB, Jones DW, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003;160:118-127.12505810","journal-title":"Am J Psychiatry"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0024-3205(99)00114-9","article-title":"The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia.","volume":"64","author":"Crook JM","year":"1999","unstructured":"Crook JM, Dean B, Pavey G, Copolov D. The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 1999;64:1761-1771.10353630","journal-title":"Life Sci"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1021\/jm990607u","article-title":"Therapeutic opportunities for muscarinic receptors in the central nervous system.","volume":"43","author":"Felder CC","year":"2000","unstructured":"Felder CC, Bymaster FP, Ward J, DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem 2000;43:4333-4353.11087557","journal-title":"J Med Chem"},{"key":"e_1_3_5_13_2","first-page":"271","article-title":"Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.","volume":"269","author":"Shannon HE","year":"1994","unstructured":"Shannon HE, Bymaster FP, Calligaro DO, et al. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther 1994;269:271-281.7909557","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1021\/acschemneuro.9b00335","article-title":"Striatal, hippocampal, and cortical networks are differentially responsive to the M4- and M1-muscarinic acetylcholine receptor mediated effects of xanomeline.","volume":"10","author":"Thorn CA","year":"2019","unstructured":"Thorn CA, Moon J, Bourbonais CA, et al. Striatal, hippocampal, and cortical networks are differentially responsive to the M4- and M1-muscarinic acetylcholine receptor mediated effects of xanomeline. ACS Chem Neurosci 2019;10:3910-3910.31286767","journal-title":"ACS Chem Neurosci"},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.drudis.2019.08.009","article-title":"Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders.","volume":"24","author":"Erskine D","year":"2019","unstructured":"Erskine D, Taylor J-P, Bakker G, Brown AJH, Tasker T, Nathan PJ. Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. Drug Discov Today 2019;24:2307-2314.31499186","journal-title":"Drug Discov Today"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.","volume":"54","author":"Bodick NC","year":"1997","unstructured":"Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473.9109749","journal-title":"Arch Neurol"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.","volume":"165","author":"Shekhar A","year":"2008","unstructured":"Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008;165:1033-1039.18593778","journal-title":"Am J Psychiatry"},{"key":"e_1_3_5_18_2","unstructured":"Sanctura (trospium chloride). Lexington MA: Indevus Pharmaceuticals 2012 (package insert)."},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1742-1241.2010.02433.x","article-title":"Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder.","volume":"64","author":"Staskin D","year":"2010","unstructured":"Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010;64:1294-1300.20561092","journal-title":"Int J Clin Pract"},{"key":"e_1_3_5_20_2","unstructured":"Kavoussi R Miller AC Brannan SK Breier A. Results of a double-blind placebo-controlled tolerability study of KarXT a novel combination targeting muscarinic acetylcholine receptors using xanomeline with trospium chloride to mitigate cholinergic side effects. Poster presented at American Society of Clinical Psychopharmacology Annual Meeting Miami Beach FL May 29\u2013June 2 2017."},{"key":"e_1_3_5_21_2","unstructured":"Brannan SK Miller AC Paul SM Breier A. KarXT a combination of the M1\/M4 cholinergic receptor agonist xanomeline and trospium for the treatment of psychosis and cognitive impairment in schizophrenia: phase I studies. Presented at poster session I of the American College of Neuropsychopharmacology 57th Annual Meeting Hollywood FL December 9\u201313 2018."},{"key":"e_1_3_5_22_2","volume-title":"Diagnostic and statistical manual of mental disorders, 5th ed.: DSM-V","year":"2013","unstructured":"Diagnostic and statistical manual of mental disorders, 5th ed.: DSM-V. Washington, DC: American Psychiatric Association, 2013."},{"key":"e_1_3_5_23_2","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan DV","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:Suppl 20:22-57.9881538","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_5_24_2","first-page":"59","article-title":"The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation.","volume":"7","author":"Kay SR","year":"1989","unstructured":"Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989;7:59-67.2619982","journal-title":"Br J Psychiatry Suppl"},{"key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","article-title":"The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia.","volume":"416","author":"Haro JM","year":"2003","unstructured":"Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003;416:16-23.12755850","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.","volume":"58","author":"Marder SR","year":"1997","unstructured":"Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546.9448657","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner K","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-1277.22193671","journal-title":"Am J Psychiatry"},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson GM","year":"1970","unstructured":"Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.4917967","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes TR","year":"1989","unstructured":"Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.2574607","journal-title":"Br J Psychiatry"},{"key":"e_1_3_5_30_2","volume-title":"Statistical power analysis for the behavioral sciences. 2nd ed","author":"Cohen J","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: L. Erlbaum, 1988."},{"key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","article-title":"Placebo response in antipsychotic clinical trials: a meta-analysis.","volume":"71","author":"Rutherford BR","year":"2014","unstructured":"Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry 2014;71:1409-1421.25321611","journal-title":"JAMA Psychiatry"},{"key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1176\/appi.ajp.2013.12030315","article-title":"Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010.","volume":"170","author":"Agid O","year":"2013","unstructured":"Agid O, Siu CO, Potkin SG, et al. Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry 2013;170:1335-1344.23896810","journal-title":"Am J Psychiatry"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2017015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:36:43Z","timestamp":1711485403000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2017015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,2,25]]}},"alternative-id":["10.1056\/NEJMoa2017015"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2017015","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739615965.793584508","asserted-by":"object"}]},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]}}}